First Allied Advisory Services’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

First Allied Advisory Services’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-500	Closed	-$23K	–	1465
2019 Q3	$23K	Buy	+500	New	+$25.6K	﹤0.01%	1451
2018 Q1	–	Sell	-531	Closed	-$24K	–	1364
2017 Q4	$24K	Buy	+531	New	+$24.9K	﹤0.01%	1383
2015 Q3	–	Sell	-45,609	Closed	-$2.66M	–	1118
2015 Q2	$2.66M	Sell	45,609 -2,653	-5%	-$152K	0.12%	202
2015 Q1	$2.66M	Sell	48,262 -665	-1%	-$35.9K	0.18%	144
2014 Q4	$2.45M	Buy	+48,927	New	+$2.39M	0.18%	141
2014 Q1	–	Sell	-17,038	Closed	-$632K	–	1044
2013 Q4	$632K	Buy	+17,038	New	+$611K	0.05%	418

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

First Allied Advisory Services's PBE Position: Q4 2019 in Review

First Allied Advisory Services sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2019, closing a stake of 500 shares — an estimated $23K sold.

First Allied Advisory Services first reported a position in PBE in Q4 2013 and held it in 6 quarters. The position peaked at $2.66M in Q1 2015. 78 funds tracked by Wall St. Rank hold PBE as of Q4 2019.

First Allied Advisory Services reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2019 after selling out during the quarter.
First Allied Advisory Services sold 500 Invesco Biotechnology & Genome ETF shares in Q4 2019, an estimated $23K.
First Allied Advisory Services first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and held it in 6 quarters.
First Allied Advisory Services's Invesco Biotechnology & Genome ETF position peaked at $2.66M in Q1 2015.
78 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2019.

Based on First Allied Advisory Services's 13F filing for Q4 2019, filed 10 Feb 2020.